Valentin Barsan
Direktor/Vorstandsmitglied bei Neuron23, Inc.
Aktive Beziehungen
Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
---|---|---|---|---|
Ken E. Drazan | M | - |
Arsenal Biosciences, Inc.
Arsenal Biosciences, Inc. Packaged SoftwareTechnology Services Arsenal Biosciences, Inc. discovers, develops, and commercializes curative immune cell therapies. It offers cell therapy, cloud computing, computational biology, genome engineering, machine learning, software engineering, and synthetic immunology. The company was founded by Ken E. Drazan, Bradley E. Bernstein, W. Nicholas Haining, Theo Roth, Kole T. Roybal, and E. John Wherry and is headquartered in San Francisco, CA. | - |
Nancy E. Stagliano | M | 57 |
Neuron23, Inc.
Neuron23, Inc. Miscellaneous Commercial ServicesCommercial Services Neuron23, Inc. is a clinical-stage biotechnology company based in an undisclosed location. The American company's focus areas are neurodegenerative diseases, neuroinflammatory diseases, and systemic autoimmune and inflammatory diseases. Neuron23 combines recent advances in human genetics with a state-of-the-art drug discovery and biomarker platform using advanced techniques in machine learning and artificial intelligence to advance therapeutics for devastating diseases. The company was founded by Adam Knight and Nancy E. Stagliano has been the CEO of the company since 2019. | 5 Jahre |
Tim Sirichoke | M | - |
Arsenal Biosciences, Inc.
Arsenal Biosciences, Inc. Packaged SoftwareTechnology Services Arsenal Biosciences, Inc. discovers, develops, and commercializes curative immune cell therapies. It offers cell therapy, cloud computing, computational biology, genome engineering, machine learning, software engineering, and synthetic immunology. The company was founded by Ken E. Drazan, Bradley E. Bernstein, W. Nicholas Haining, Theo Roth, Kole T. Roybal, and E. John Wherry and is headquartered in San Francisco, CA. | - |
Beth Seidenberg | M | 67 |
Arsenal Biosciences, Inc.
Arsenal Biosciences, Inc. Packaged SoftwareTechnology Services Arsenal Biosciences, Inc. discovers, develops, and commercializes curative immune cell therapies. It offers cell therapy, cloud computing, computational biology, genome engineering, machine learning, software engineering, and synthetic immunology. The company was founded by Ken E. Drazan, Bradley E. Bernstein, W. Nicholas Haining, Theo Roth, Kole T. Roybal, and E. John Wherry and is headquartered in San Francisco, CA. | - |
Brook Byers | M | 78 |
Arsenal Biosciences, Inc.
Arsenal Biosciences, Inc. Packaged SoftwareTechnology Services Arsenal Biosciences, Inc. discovers, develops, and commercializes curative immune cell therapies. It offers cell therapy, cloud computing, computational biology, genome engineering, machine learning, software engineering, and synthetic immunology. The company was founded by Ken E. Drazan, Bradley E. Bernstein, W. Nicholas Haining, Theo Roth, Kole T. Roybal, and E. John Wherry and is headquartered in San Francisco, CA. | - |
Matthew Fust | M | 59 |
Arsenal Biosciences, Inc.
Arsenal Biosciences, Inc. Packaged SoftwareTechnology Services Arsenal Biosciences, Inc. discovers, develops, and commercializes curative immune cell therapies. It offers cell therapy, cloud computing, computational biology, genome engineering, machine learning, software engineering, and synthetic immunology. The company was founded by Ken E. Drazan, Bradley E. Bernstein, W. Nicholas Haining, Theo Roth, Kole T. Roybal, and E. John Wherry and is headquartered in San Francisco, CA. | 3 Jahre |
Jim Scopa | M | 65 |
Neuron23, Inc.
Neuron23, Inc. Miscellaneous Commercial ServicesCommercial Services Neuron23, Inc. is a clinical-stage biotechnology company based in an undisclosed location. The American company's focus areas are neurodegenerative diseases, neuroinflammatory diseases, and systemic autoimmune and inflammatory diseases. Neuron23 combines recent advances in human genetics with a state-of-the-art drug discovery and biomarker platform using advanced techniques in machine learning and artificial intelligence to advance therapeutics for devastating diseases. The company was founded by Adam Knight and Nancy E. Stagliano has been the CEO of the company since 2019. | - |
Sean Parker | M | 44 |
Arsenal Biosciences, Inc.
Arsenal Biosciences, Inc. Packaged SoftwareTechnology Services Arsenal Biosciences, Inc. discovers, develops, and commercializes curative immune cell therapies. It offers cell therapy, cloud computing, computational biology, genome engineering, machine learning, software engineering, and synthetic immunology. The company was founded by Ken E. Drazan, Bradley E. Bernstein, W. Nicholas Haining, Theo Roth, Kole T. Roybal, and E. John Wherry and is headquartered in San Francisco, CA. | - |
Raidy Kevin J. | M | 55 |
Neuron23, Inc.
Neuron23, Inc. Miscellaneous Commercial ServicesCommercial Services Neuron23, Inc. is a clinical-stage biotechnology company based in an undisclosed location. The American company's focus areas are neurodegenerative diseases, neuroinflammatory diseases, and systemic autoimmune and inflammatory diseases. Neuron23 combines recent advances in human genetics with a state-of-the-art drug discovery and biomarker platform using advanced techniques in machine learning and artificial intelligence to advance therapeutics for devastating diseases. The company was founded by Adam Knight and Nancy E. Stagliano has been the CEO of the company since 2019. | - |
Michael Polansky | M | - |
Arsenal Biosciences, Inc.
Arsenal Biosciences, Inc. Packaged SoftwareTechnology Services Arsenal Biosciences, Inc. discovers, develops, and commercializes curative immune cell therapies. It offers cell therapy, cloud computing, computational biology, genome engineering, machine learning, software engineering, and synthetic immunology. The company was founded by Ken E. Drazan, Bradley E. Bernstein, W. Nicholas Haining, Theo Roth, Kole T. Roybal, and E. John Wherry and is headquartered in San Francisco, CA. | 5 Jahre |
Kathy Dong | M | - |
Neuron23, Inc.
Neuron23, Inc. Miscellaneous Commercial ServicesCommercial Services Neuron23, Inc. is a clinical-stage biotechnology company based in an undisclosed location. The American company's focus areas are neurodegenerative diseases, neuroinflammatory diseases, and systemic autoimmune and inflammatory diseases. Neuron23 combines recent advances in human genetics with a state-of-the-art drug discovery and biomarker platform using advanced techniques in machine learning and artificial intelligence to advance therapeutics for devastating diseases. The company was founded by Adam Knight and Nancy E. Stagliano has been the CEO of the company since 2019. | 2 Jahre |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Statistik
Land | Beziehungen | % des Gesamten |
---|---|---|
Vereinigte Staaten | 11 | 100,00% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
- Börse
- Insiders
- Valentin Barsan
- Persönliches Netzwerk